Drugs / Zenapax
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Zenapax | — | 2009-01-01 | europa.eu ↗ |
| Approved | EU (EMA) | Zenapax | — | 1999-02-26 | europa.eu ↗ |
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00198146 | Jul 2000 → Feb 2007 | — | Indiana University | Completed | No outcome recorded |
| Phase 2 | NCT00001934 | Sep 1999 → Aug 2005 | multiple sclerosis | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00048152 | Dec 2000 → Mar 2006 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00138970 | Jan 2002 → Feb 2005 | disease related to solid organ transplantation | University of Oslo School of Pharmacy | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zenapax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00138970 ↗ |
| Known as | Daclizumab | “A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients” NCT00048152 ↗ |
| Action | Inhibit | “a humanized antibody against the IL-2Ra subunit (Zenapax(Registered Trademark)) will be used to inhibit T cell activation in MS patients” NCT00001934 ↗ |
| Modality | Monoclonal antibody | “Effect of the Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (IL-2R-Alpha; Zenapax(Registered Trademark)) on Inflammatory Activity in the CNS in...” NCT00001934 ↗ |
| Route | Intravenous | “During treatment, patients will receive seven intravenous (I.V.) infusions of Zenapax in the clinic.” NCT00001934 ↗ |
| Target | IL2RA | “a humanized antibody against the IL-2Ra subunit (Zenapax(Registered Trademark))” NCT00001934 ↗ |